← 返回前沿论文

CD24 在多种癌症中影响肿瘤浸润细胞的免疫抑制效应和肿瘤耐药性

英文原题:CD24 affects the immunosuppressive effect of tumor-infiltrating cells and tumor resistance in a variety of cancers.

PubMed 2024/09/02(内容时间) Discov Oncol Q3 · IF 2.8(JCR 2025)

研究概要

CD24参与免疫浸润的调节,影响患者预后,并可作为潜在的肿瘤标志物。

研究思路结论见上方概要

分化簇24(CD24)是一种高度糖基化的糖基磷脂酰肌醇(GPI)锚定表面蛋白,在多种肿瘤细胞中表达,作为肿瘤免疫中的“别吃我”信号分子。本研究旨在探讨CD24在泛癌中的潜在特征。

采用TIMER分析评估22种免疫细胞与CD24表达之间的相关性。使用R包"ESTIMATE"预测泛癌中免疫细胞和基质细胞的比例。采用Spearman相关性分析评估CD24表达与免疫检查点、趋化因子、错配修复、肿瘤突变负荷和微卫星不稳定性之间的关系,并进行qPCR和western blot评估肝细胞癌(LIHC)中CD24的表达水平。此外,通过功能缺失实验对CD24在LIHC中的生物学功能进行评价。

CD24表达与多种肿瘤中的髓系细胞正相关,包括中性粒细胞和髓源性抑制细胞,如BLCA、HNSC-HPV、HNSC、KICH、KIRC、KIRP、TGCT、THCA、THYM和UCEC。相反,抗肿瘤NK细胞和NKT细胞在BRCA-Her2、ESCA、HNSC-HPV、KIRC、THCA和THYM中与CD24表达呈负相关。CD24与ImmuneScore相关性最高的前三种肿瘤为TGCT、THCA和SKCM。功能富集分析显示,CD24表达与多种免疫相关通路呈负相关。在CESC、CHOL、COAD、ESCA、READ、TGCT和THCA中,免疫检查点和趋化因子也与CD24呈负相关。此外,CD24在大多数肿瘤中过表达,其中BRCA、LIHC和CESC中CD24高表达与不良预后相关。TIDE数据库表明,CD24高表达的肿瘤,尤其是黑色素瘤,对PD1/PD-L1免疫治疗反应较差。最后,敲低CD24导致LIHC中增殖和细胞周期进程受损。

展开英文摘要原文

BACKGROUND: Cluster of differentiation 24 (CD24) is a highly glycosylated glycosylphosphatidylinositol (GPI)-anchored surface protein, expressed in various tumor cells, as a "don't eat me" signaling molecule in tumor immune. This study aimed to investigate the potential features of CD24 in pan-cancer. METHODS: The correlations between 22 immune cells and CD24 expression were using TIMER analysis. R package "ESTIMATE" was used to predict the proportion of immune and stromal cells in pan-cancer. Spearman's correlation analysis was performed to evaluate the relationships between CD24 expression and immune checkpoints, chemokines, mismatch repair, tumor mutation burden and microsatellite instability, and qPCR and western blot were conducted to assess CD24 expression levels in liver hepatocellular carcinoma (LIHC). In addition, loss of function was performed for the biological evaluation of CD24 in LIHC. RESULTS: CD24 expression was positively correlated with myeloid cells, including neutrophils and myeloid-derived suppressor cells, in various tumors, such as BLCA, HNSC-HPV, HNSC, KICH, KIRC, KIRP, TGCT, THCA, THYM, and UCEC. In contrast, anti-tumor NK cells and NKT cells showed a negative association with CD24 expression in BRCA-Her2, ESCA, HNSC-HPV, KIRC, THCA, and THYM. The top three tumors with the highest correlation between CD24 and ImmuneScore were TGCT, THCA, and SKCM. Functional enrichment analysis revealed CD24 expression was negatively associated with various immune-related pathways. Immune checkpoints and chemokines also exhibited inverse correlations with CD24 in CESC, CHOL, COAD, ESCA, READ, TGCT, and THCA. Additionally, CD24 was overexpressed in most tumors, with high CD24 expression in BRCA, LIHC, and CESC correlating with poor prognosis. The TIDE database indicated tumors with high CD24 expression, particularly melanoma, were less responsive to PD1/PD-L1 immunotherapy. Finally, CD24 knockdown resulted in impaired proliferation and cell cycle progression in LIHC. CONCLUSION: CD24 participates in regulation of immune infiltration, influences patient prognosis and serves as a potential tumor marker.

论文信息

作者
Zhao C、Huang Y、Zhang H、Liu H
第一作者单位
Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu Province, China.China
通讯作者单位
Department of Clinical Laboratory, Affiliated Nantong Hospital 3 of Nantong University, Nantong Third People's Hospital, Nantong, Jiangsu, China. huiminliu88@hotmail.com.China
期刊
Discover oncology2024 Sep 2
原文标识
PubMed 39222166 · DOI 10.1007/s12672-024-01284-7